Pursuant to the Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), and amendments thereto, this is to inform that the Meeting of the Board of Directors of the Company held today i.e., on Thursday, 05th November, 2026, which commenced at 03:30 PM, and concluded at 04:00 PM, Board, inter-alia, approved and taken on record the following: 1. ....

== EIKO LIFESCIENCES LIMITED B FeEEL THE CHEMISTRY Date: 05t November, 2026 Corporate Services Department, BSE Limited, Phiroze Jeejeebhoy Towers, 1st Floor, Dalal Street, Fort, Mumbai - 400001. Scrip Code: 540204 Subject: Outcome of the Board Meeting Dear Sir/Madam, Pursuant to the Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), and amendments thereto, this is to inform that the Meeting of the Board of Directors of the Company held today i.e., on Thursday, 05t November, 2026, which commenced at 03:30 PM, and concluded at 04:00 PM, Board, inter-alia, approved and taken on record the following: 1. Approved Un-Audited Standalone and Consolidated Financial Results for the quarter and Half- year ended 30t September, 2026 along with Limited Review Report issued by the Statutory Auditors of the Company. A Copy of the same is enclosed herewith as Annexure - 1. 2. Considered and approved the investment by Eiko Scientific Solutions LLP (Wholly Owned Subsidiary of the Company) for formation of a new 50-50 Joint Venture (Private Limited) Company with Oval Projects Engineering Limited, to carroyn business in the name of Oval Eiko Resources Private Limited. (Proposed Company) Disclosure as required under Regulation 30 of the Listing Regulations read with SEBI Master Circular No.HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated 30t January, 2026 and other applicable circulars, if any, is enclosed herewith as Annexure II. Thanking you, For Eiko Lifesciences Limited Chintan Doshi Company Secretary and Compliance Officer Membership No: A36190 Eiko LifeSciences Limited, CIN: L65993MH1977PLC258134 Registered Address: 604, Centrum, Opp. TMC Office, Near Satkar Grande Hotel, Wagle Estate, Thane MH 400604 Mobile No.: +919082668855; Email id: investor.relations@eikolifesciences.com website: www.eikolifesciences.com Annexure-| P SV Jain & Associates Chartered Accountants Yashwant Shopping Centre, 126, Carter Rd No. 7, Chinchpada, Borivali East, Mumbai, Maharashtra 400066 INDIA Independent Auditor's Review Report on Standalone Unaudited Financial Results Quarter and Half Year Ended 30* September 20o2f t6he Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) To the Board of Directors Eiko LifeSciences Limited 1. We have reviewed the accompanying statement of standalone unaudited financial results (‘the Statement') of Eiko Lifesciences Limited (The Company') for the Quarter and Half Year Ended 30" September 2026 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations'). 2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial result prepared in accordance with applicable Principles laid down in Indian Accounting Standards 34 "Interim Financial Reporting” ("Ind AS 34") prescribed under section 133 of companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 read with the Circular, includitnhge manner in which it is to be disclosed, or that it contains any material misstatement. For PSV JAIN & ASSOCIATES Chartered Accountants Firm Registration No.: 131505W CA Dularesh Kumar Jain Partner Place: Thane Membership No.: 137264 Date: 5™ November 2026 UDIN: 26137264RHKD12J0S5 EIKO LIFESCIENCES LIMITED (CIN: L65993MH1977PLC258134) Standalone Statement of Profit and Loss for the Quarter and Half Year Ended 30-09-2026 (INRin lakhs) Quarter ended Half Year Ended Year Ended Sr. 30.09.2026 30.06.2026 30.09.2025 30.09.2026 30.09.2026 31.03.2026 Particulars (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) 1,465.96 1,417.81 919.74 2,883.78 1,664.97 4,212.68 Revenue from operations 48.29 68.34 56.47 116.63 111.85 212.93 Other income 1,514.25 1,486.15 976.21 3,000.41 1,776.81 4,425.61 Totalrevenue Expenses 1,193.95 1,324.50 862.70 2,518.45 1,322.75 3,728.41 Cost of material consumed Changes in inventories of finished stock and work-in-progress 109.85 (40.96) (56.23) 68.89 140.15 131 Employee benefits expense 7.82 7.16 7.03 14.97 12.88 29,01 14.75 14.74 14.76 29.49 29,51 59.02 Depreciation and amortization expense 7.34 4.06 6.97 11.40 8.79 16.29 Finance Cost Other expenses 36.89 36.21 34.18 73.10 65.15 120.28 1,370.59 1,345.71 869.41 2,716.29 1,579.23 3,954.31 Totalexpenses Profit/(Loss) before Exceptional ltems and tax 143.66 140.45 106.80 284.11 197.58 471.30 Exceptional ltems Profit/(Loss) before Tax 143.66 140.45 106.80 284.11 197.58 471.30 5 Tax expense: 3115 32.65 2284 63.80 4277 104.93 (1) Current tax (2) Deferredtax 136 136 221 272 3.83 8.25 Net Profit/(Loss) after tax 111.15 106.44 81.76 217.59 150.98 358.11 Other Comprehensive Income (OCI) o Total Other Comprehensive Income (OCI) 111.15 106.44 81.76 217.59 150.98 358.11 o Paid up Equity Share Capital 1,465.09 1,434.59 1,372.09 1,465.09 1,372.09 1,465.09 Other Equity 4,909.65 B Earnings Per Share (EPS) (Not annualised) (1) Basic 077 074 0.60 151 1.10 2.48 (2) Diluted 0.64 062 0.60 1.26 110 2.07 NOTES 1 The Standalone Financial Results for the Quarter and Half Year ended 30" September 2026 were reviewed by the Audit Committee and recommended to the Board, which was thereafter approved by the Board of Directors of the Company at its meeting held on 05" November 2026. The company has a single business segment, namely "Speciality & Fine Chemicals", therefore in the context of Ind AS 108, disclosure of segment information is not applicable. Figures for the previous period have been regrouped/ reclassified wherever necessary to conform to current period's classification. For Eiko LifeSciences Limited Lele Cand Laxmikant Kabra Chairman DIN: 00061346 Date: 05" November 2026 Place: Thane EIKO LIFESCIENCES LIMITED (CIN: L65993MH1977PLC258134) Standalone Balance Sheet as of Quarter and Half Year ended 30-09-2026 (INRin lakhs) Particulars As of As of 30-09-2026 31-03-2026 ASSETS Non-current assets Property, Plant and Equipment 1,337.72 1,367.21 Financial Assets Investments [Showing first 8,000 characters — download PDF for full document]